Abstract Details

Title Randomized Phase 2B trial of NP001, a Novel Immune Regulator, in ALS

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) S38 - (-)

Poster/Presentation
Number 004

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Robert G. Miller, MD (Dept Of Neurology, CA Pacific) PRESENTER	The institution of Dr. Miller has received research support from Nurown.
Jonathan S. Katz, MD (CPMC)	Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Calico. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenyx. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Katz has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Griffols. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Katz has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion.
Gilbert A. Block, MD, PhD (The Willmatt Group)	No disclosure on file
	No disclosure on file